ArticleMicroorganisms2021
Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- In Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade ofJournal of fungi (Basel, Switzerland) · 2026Article
- The in vitro activity of iron chelator deferiprone against Candida (Candidozyma) auris in combination with antifungal agents.Medical mycology · 2025Article
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Chitosan-Based Hydrogels Containing Nystatin and Propolis as a Novel Tool forGels (Basel, Switzerland) · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against FourJournal of fungi (Basel, Switzerland) · 2024Article
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Efficacy of the combination of amphotericin B and echinocandins againstMicrobiology spectrum · 2024Article
- Various Biomimetics, Including Peptides as Antifungals.Biomimetics (Basel, Switzerland) · 2023Review
- Broad susceptibility ofmBio · 2023Article
- Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida aurisAntimicrobial agents and chemotherapy · 2023Article
- Rezafungin: First Approval.Drugs · 2023Review
- PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.CPT: pharmacometrics & systems pharmacology · 2023Article
- In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against FourPharmaceutics · 2023Article
- Antifungal chemotherapies and immunotherapies for the future.Parasite immunology · 2023Review
- Small molecules for combating multidrug-resistant superbugActa pharmaceutica Sinica. B · 2022Review
- Recent Antifungal Pipeline Developments againstJournal of fungi (Basel, Switzerland) · 2022Review
- Postantifungal Effect of Antifungal Drugs againstJournal of fungi (Basel, Switzerland) · 2022Review
- In Vivo Efficacy of Amphotericin B against FourJournal of fungi (Basel, Switzerland) · 2022Article
- Topical Dosage Formulation of LyophilizedMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.